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samuel Myllykangas2,8, Karin van spaendonck-Zwarts4, J. Peter van tintelen  4,9,  
Paul A. van der Zwaag5 & Juha Koskenvuo8
Recent advancements in next generation sequencing (NGS) technology have led to the identification 
of the giant sarcomere gene, titin (TTN), as a major human disease gene. Truncating variants of TTN 
(TTNtv) especially in the A-band region account for 20% of dilated cardiomyopathy (DCM) cases. Much 
attention has been focused on assessment and interpretation of TTNtv in human disease; however, 
missense and non-frameshifting insertions/deletions (NFS-INDELs) are difficult to assess and interpret 
in clinical diagnostic workflow. Targeted sequencing covering all exons of TTN was performed on a 
cohort of 530 primary DCM patients from three cardiogenetic centres across Europe. Using stringent 
bioinformatic filtering, twenty-nine and two rare TTN missense and NFs-INDeLs variants predicted 
deleterious were identified in 6.98% and 0.38% of DCM patients, respectively. However, when 
compared with those identified in the largest available reference population database, no significant 
enrichment of such variants was identified in DCM patients. Moreover, DCM patients and reference 
individuals had comparable frequencies of splice-region missense variants with predicted splicing 
alteration. DCM patients and reference populations had comparable frequencies of rare predicted 
deleterious TTN missense variants including splice-region missense variants suggesting that these 
variants are not independently causative for DCM. Hence, these variants should be classified as likely 
benign in the clinical diagnostic workflow, although a modifier effect cannot be excluded at this stage.
With a prevalence of at least 1:2500, dilated cardiomyopathy (DCM) is a relatively common cause for heart failure 
and sudden cardiac death, and the most prevalent indication for heart transplantation1,2. DCM is characterized 
by progressive left ventricular dilatation and systolic dysfunction. Based on aetiology, the European Society of 
Cardiology (ESC) classified DCM into familial (genetic) and non-familial forms, with up to 30–50% of idiopathic 
DCM cases being familial3,4. Familial DCM exhibits genetic heterogeneity and follows generally an autosomal 
dominant inheritance. Most of the disease-causing DCM variants have been identified in genes encoding the 
components of the sarcomere, desmosome, cytoskeleton, nuclear lamina, mitochondria, and calcium-handling 
proteins5,6.
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Variants leading to truncations of the giant sarcomeric protein titin (TTNtv) are the most frequent cause of 
DCM. Recently, we and others have identified clinically relevant TTNtv in about 20% of unselected and familial 
DCM cases7–10. Interestingly, DCM-causing TTNtv are clustered in the clinically relevant A-band region of the 
gene whereas TTNtv in reference and healthy individuals are clustered more in the I-band region where they 
may be spliced out, due to the usage of an alternative promoter, from mature long TTN isoforms resulting in 
minimal or no functional consequences11. Interpretation of TTNtv in clinical setting has been challenged by 
several factors including lack of knowledge of the true frequency of TTNtv in the general population, lack of 
understanding of different protein domains and alternatively spliced isoforms, and variable disease presentation 
hampering assessment of co-segregation. We and others have previously addressed these issues7,9,12–14. However, 
assessing the relevance of TTN missense variants in the pathogenesis of DCM has been even more difficult due 
to the high frequency of these variants in both reference individuals and DCM patients and the absence of large 
pedigrees where segregation can be studied. While few studies have reported modifier roles for TTN missense 
variants15,16, others have considered TTN missense variants as disease-causing variants in DCM, arrhythmogenic 
right ventricular cardiomyopathy (ARVC), and left ventricular non-compaction cardiomyopathy (LVNC) but 
these observations suggest recessive inheritance pattern and no convincing segregation has been demonstrated 
so far17–19. Furthermore, TTNtvs are also occasionally found in patients with SCD/aborted SCD who do not have 
diagnosis of DCM or DCM with LVNC20,21
In the current study, we focused on TTN missense and non-frameshifting insertion-deletion (NFS-INDELs) 
variants identified in DCM patients and reference population. By analyzing TTN missense and NFS-INDELs 
variants identified in 530 primary DCM patients, over 60,000 ExAC individuals, and for the first time, the largest 
available 123,136 gnomAD database reference individuals, we report a seemingly insignificant enrichment of 
TTN missense variants in DCM patients compared with reference individuals.
Results
Patient Cohort. DCM patients in this multi-centre study were recruited from three major cardiogenetic 
centres in Finland and the Netherlands. All patients fulfilled diagnostic criteria for DCM. Table 1 summarizes 
spectrum of pathogenic and likely pathogenic variants identified in the patients.
Deriving Allele Frequency for Potentially Deleterious DCM Variant. To set a threshold for filtering 
TTN missense variants identified in DCM cohorts, we obtained the gnomAD allele frequency of the most com-
mon pathogenic variant associated with DCM with a wide consensus of the pathogenicity in the field. Covering 
100% of the total gnomAD alleles, the PLN c.40_42delAGA, p.Arg14del (NM_002667.4) variant is the most 
common “certainly pathogenic” DCM variant22–26. This variant is absent in the ExAC individuals (allele count 
[AC] = 0), while it is present in two individuals (AC = 2) in the gnomAD database. Based on these observations, 
the minor allele frequency (MAF) cut-offs were set to 0.0016% (AC = 2) and 0.0016% (AC = 4) for ExAC and 
gnomAD datasets respectively, and variants with higher frequency in the reference populations would not be 
expected to be pathogenic.
TTN NFS-INDELs and Missense Variants in DCM Cohort. Initial variant calling with GATK yielded 
a total of 1402 unique TTN variants identified in 530 primary DCM patients, of which 506 were missense and 
Patients All (N = 530)
Helsinki cohort 
(N = 145)
Groningen cohort 
(N = 169)
Amsterdam cohort 
(N = 216)
Gender distribution, n (%)
Males 311 (58.7) 107 (73.8) 95 (56.2) 109 (50.5)
Females 219 (41.3) 38 (26.2) 74 (43.8) 107 (49.5)
Diagnostic yield, n (%)
Mutation positive 157 (29.6) 51 (35.2) 37 (21.9) 69 (31.9)
Mutation negative 373 (70.4) 94 (64.8) 137 (81.1) 147 (68.1)
Causative gene, n (%)
Sarcomeric 108 (20.4) 28 (19.3) 22 (13.0) 58 (26.9)
TPM1 1 (0.2) — — 1 (0.5)
TCAP 1 (0.2) 1 (0.7) — —
TNNT2 2 (0.4) 1 (0.7) — 1 (0.5)
TNNI3 2 (0.4) — — 2 (0.9)
MYH7 5 (0.9) 1 (0.7) 2 (1.2) 2 (0.9)
TTN 97 (18.3) 25 (17.2) 20 (11.8) 52 (24.1)
Non-sarcomeric 49 (9.2) 23 (15.7) 15 (8.9) 11 (5.1)
DMD 1 (0.2) 1 (0.7) — —
RBM20 10 (1.9) 2 (1.4) 3 (1.8) 5 (2.3)
PLN 11 (2.1) — 7 (4.1) 4 (1.9)
DSP 12 (2.3) 8 (5.5) 2 (1.2) 2 (0.9)
LMNA 15 (2.8) 12 (8.3) 3 (1.8) —
Table 1. Distribution and spectrum of other pathogenic and likely pathogenic variants identified in the cohort.
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NFS-INDELs (Fig. 1), 39 frameshift variants, 27 nonsense variants, 14 splice-site variants, 205 silent variants, 
4 untranslated region (UTR) variants, and the remaining 607 variants being intronic. Of the total variants, 
52.7% were private (Fig. 2). Applying the ExAC and gnomAD MAF cut-offs yielded a total of 87 missense and 5 
NFS-INDEL variants. Taken together, 18.9% and 1.9% of DCM patients carried rare heterozygous missense and 
NFS-INDELs, respectively. Given that many rare and even private variants are believed to be innocent bystand-
ers, variant pathogenicity potential was further assessed by using three in-silico prediction tools. Implementing 
this, 33.3% (29/87) of the rare missense variants were predicted deleterious. Interestingly, 69.0% (20/29) of the 
predicted deleterious missense variants were in the A-band region of TTN. Of note, 55.2% (16/29) of the rare 
missense variants were absent in both ExAC and gnomAD reference individuals.
Figure 1. Bioinformatic filtering strategy to identify “deleterious” variants. Total TTN variants were filtered 
using allele frequency (0.0016%) threshold derived from the frequency of known pathogenic DCM variants 
identified in gnomAD reference individuals. Variants more frequent than derived thresholds in respective 
sources were not expected to be deleterious.
Figure 2. Allele frequency spectrum of TTN missense variants in DCM and reference individuals. More than 
50% of TTN missense variants in DCM patients as well as in reference individuals were private. Potentially 
pathogenic private and/or rare TTN missense variants were not enriched in DCM patients compared with 
ExAC and gnomAD reference individuals.
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Twenty-nine rare heterozygous TTN missense variants predicted deleterious were identified in 6.8% (36/530) 
of DCM patients, with only one patient harbouring two rare heterozygous TTN missense variants. Heterozygous 
NFS-INDELS affecting at least five transcripts of the TTN (Transcript Count Index, TCI ≥ 5) were identified in 
0.37% (2/530) of DCM patients. Of note, all the NFS-INDELS were in the I-band region of TTN (Tables 2 and 3). 
When considering mutation status, gene elusive DCM patients and mutation positive DCM patients had com-
parable frequencies of rare TTN missense variants further suggesting that these variants may not be monogenic 
cause of DCM (Supplemantary Table S1).
TTN Missense and NFS-INDELs Variants in Reference Population. Applying the derived allele fre-
quency thresholds to TTN variants reported in ExAC, we identified 8265 and 82 rare missense and NFS-INDELs 
variants respectively in 16.5% (10035/60707) and 0.15% (93/60707) of the ExAC individuals. Of the ExAC rare 
missense variants, 24% (1990/8265) were predicted deleterious by the three prediction tools used in this study. In 
total, 3.98% of ExAC individuals carried a rare TTN missense variant predicted deleterious. In addition, 0.11% 
(65/60706) of ExAC cohort harboured rare heterozygous NFS-INDELs affecting at least five transcripts of TTN.
Given that gnomAD cohort is almost twice the size of ExAC cohort and ExAC individuals are in gnomAD 
cohort, we set the threshold to four and considered variants more frequent than this in gnomAD as likely 
benign. With this threshold, we identified 13808 rare missense variants present in 17.1% (21102/123136) of gno-
mAD cohort. However, rare heterozygous TTN missense variants predicted deleterious were observed in 5.7% 
(7071/123136) of the gnomAD (Table 2). Notably, 54.6% and 52.2% of TTN missense and NFS-INDELS identified 
in ExAC and gnomAD cohorts respectively were private (Fig. 2).
Multiple Heterozygous TTN Variants. To estimate the frequency of reference individuals with multi-
ple heterozygous TTN variants, the phase 3 call set of the 1000 Genomes project was utilized since it provides 
sample-level genotype data. Only TTN missense variants with allele frequency less than or equal the derived 
thresholds were used for this analysis. We identified 8.2% (205/2504) of the 1000 Genomes Project phase 3 
cohorts with a rare heterozygous TTN missense variant. Of these, 5.4% (11/205) harboured two heterozygous 
rare TTN missense variants.
When considering eleven individuals in 1000 Genomes Project phase 3 cohorts with TTN truncations 
(TTNtv) as published previously12, 18.2% (2/11) of these individuals, both from South Asian population also 
harboured a rare heterozygous TTN missense variant, thus, being heterozygous for both rare TTNtv and TTN 
missense variant. However, it is unclear whether they are in cis (at the same allele) or in trans (at different allele)
Interestingly, only one DCM patient in this study harboured two rare heterozygous TTN missense variants, 
one in the A-band and the other at the distal I-band TTN region. Five out of thirty-six (13.9%) DCM patients with 
rare TTN missense variants predicted deleterious harbored a TTNtv (Table 4).
Distribution of TTN NFS-INDELs and Missense Variants in DCM and Reference Cohorts. The 
proportion of DCM patients harbouring rare TTN missense and NFS-INDEL variants before and after variant 
assessment was compared with that identified in the reference population. 18.9% (100/530) of DCM patients 
harboured rare TTN missense variants as against 17.3% in gnomAD reference individuals (OR = 1.1; 95% 
Total TTN NFS-INDEL allele Total TTN missense allele
DCM 
(n = 530)
gnomAD 
(n = 123,136) OR p-value
DCM 
(n = 530)
gnomAD 
(n = 123,136) OR p-value
Raw variant (before assessment)
   Unique variant count 9 289 497 17726
After assessment using derived thresholds
   Unique variant count 5 226 87 13808
   Number of individuals (n) 10 337 100 21102
   Prevalence (%) 1.887 0.273 7.0 3.2E-06 18.867 17.137 1.1 0.3187
Distribution by sarcomere domain, n (%)
   Z-disc 0 (0.00) 32 (0.026) NA 2 (0.377) 1074 (0.872) 0.4 0.3400
   I-band 10 (1.887) 104 (0.084) 22.7 8.7E-11 46 (8.679) 6720 (5.457) 1.6 0.0015
   A-band 0 (0.00) 137 (0.111) NA 58 (10.943) 10725 (8.709) 1.3 0.0815
   M-band 0 (0.00) 53 (0.043) NA 2 (0.377) 1488 (1.208) 0.3 0.1000
After assessment using derived thresholds and pathogenicity prediction
   Unique variant count 2 172 29 4657
   Number of individuals (n) 2 255 37 7071
   Prevalence (%) 0.377 0.207 1.8 0.3000 6.981 5.74 1.2 0.2200
Distribution by sarcomere domain, n (%)
   Z-disc 0 (0.00) 31 (0.025) NA 1 (0.188) 243 (0.197) 0.95 1.0000
   I-band 2 (0.377) 30 (0.024) 15.5 0.0083 10 (1.887) 1486 (1.206) 1.6 0.1581
   A-band 0 (0.00) 137 (0.111) NA 25 (4.717) 4760 (3.865) 1.2 0.3100
   M-band 0 (0.00) 53 (0.043) NA 0 540 (0.438) NA NA
Table 2. TTN missense and non-frameshifting INDELs variants in DCM vs. general population.
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CI: 0.90–1.35; P = 0.32). Moreover, DCM patients had a slightly higher frequency of TTN missense in the 
TTN I-band region (8.7% vs. 5.5%; OR = 1.1; 95% CI: 1.2–2.1; P = 0.0015) and A-band region (10.9% vs. 8.7%; 
OR = 1.3; 95% CI: 1.0–1.6; P = 0.08). Rare NFS-INDELs was detected in 1.9% of DCM patients as against 0.3% in 
gnomAD reference individuals (OR = 7.0; P = 3.2 × 10−6). Of note, all NFS-INDELs identified in DCM patients 
clustered in the TTN I-band region. When considering rare TTN missense and NFS-INDELs together, there 
was no statistically significant enrichment of these variants in DCM patients and within TTN domains com-
pared to the observed frequency and distribution in gnomAD database reference individuals (Table 2 and Fig. 3). 
Moreover, distribution of TTN missense variants was similar in patients with a known pathogenic or likely path-
ogenic DCM mutation (Mutation positive) compared to those without a mutation (Mutation negative) when the 
variant classification follows ACMG criteria (Supplementary Table S1).
SYMBOL Position
Nucleotide 
Change AA Change EXON
DCM 
(n)
ExAC 
(n)
gnomAD 
(n)
Z-disk
   TTN 179664242 c.886 G > A Val296Met 6 1 0 0
I-band
   TTN 179640476 c.6115 C > T Leu2039Phe 28 1 0 0
   TTN 179634837 c.8591 A > G Tyr2864Cys 36 1 0 0
   TTN 179634555 c.8753 G > C Gly2918Ala 37 1 1 2
   TTN 179632835 c.9211 G > C Glu3071Gln 39 1 2 4
   TTN 179588312 c.21515 G > T Arg7172Ile 74 3 0 0
   TTN 179576946 c.27611 C > T Pro9204Leu 96 1 1 2
   TTN 179574299 c.28747 A > T Ile9583Phe 99 1 0 0
   TTN 179494979 c.44270 T > A Leu14757His 239 2 0 0
A-band
   TTN 179477634 c.49814 T > G Val16605Gly 265 6 0 0
   TTN 179476201 c.50755 G > T Val16919Phe 269 1 0 0
   TTN 179472191 c.53224 T > A Tyr17742Asn 277 1 0 0
   TTN 179452778 c.63356 G > A Cys21119Tyr 305 1 1 1
   TTN 179441303 c.69668 G > C Gly23223Ala 325 1 0 0
   TTN 179425479 c.85380 A > G Ile28460Met 326 1 1 3
   TTN 179429090 c.81769 C > A Pro27257Thr 326 0 0 0
   TTN 179432751 c.78108 G > C Leu26036Phe 326 1 0 1
   TTN 179435376 c.75483 G > C Lys25161Asn 326 1 0 1
   TTN 179436260 c.74599 A > G Thr24867Ala 326 1 0 0
   TTN 179439256 c.71603 G > A Arg23868Gln 326 1 1 2
   TTN 179439440 c.71419 T > C Tyr23807His 326 1 0 0
   TTN 179419452 c.88622 T > C Ile29541Thr 332 1 1 4
   TTN 179416971 c.90656 T > A Val30219Asp 335 1 0 0
   TTN 179417593 c.90034 G > A Glu30012Lys 335 1 0 0
   TTN 179418010 c.89617 T > C Trp29873Arg 335 1 0 0
   TTN 179414844 c.91721 A > T Glu30574Val 337 2 0 1
   TTN 179414390 c.92059 G > A Gly30687Ser 338 1 2 4
   TTN 179411891 c.94361 T > C Leu31454Pro 340 1 0 0
   TTN 179403949 c.98713 G > A Glu32905Lys 353 1 1 3
Table 3. Rare TTN missense variant classified as deleterious by in-silico prediction. Variant positions were 
reported for the RefSeq transcript NM_001267550.
Gene
Deleterious TTN missense variants Other known P/LP TTNtv
Nucleotide 
Change AA Change
Nucleotide 
Change AA Change
TTN c.44270 T > A p.Leu14757His c.45322 C > T p.Arg15108*
TTN c.91721 A > T p.Glu30574Val c.76373delC p.Pro25458Glnfs*9
TTN c.98713 G > A p.Glu32905Lys c.8426dup p.Asn2809Lysfs*7
TTN c.69668 G > C p.Gly23223Ala c.69671delC p.Pro23224HisfsTer10
TTN c.49814 T > G p.Val16605Gly c.75391delG p.V25131Lfs*16
Table 4.  DCM patients with both predicted deleterious TTN missense variant and TTN truncation (TTNtv). 
Variant positions were reported for the RefSeq transcript NM_001267550.
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Splice-Region Missense Variants with Predicted Splicing Effect are not enriched in DCM. Given 
that variants that affect splicing can directly cause disease or contribute to disease severity, we analysed missense 
variants located near exon-intron boundaries (splice-regions). A total of five rare splice-region missense variants 
affecting 3.6% (19/530) of DCM patients was identified. Of note, only two out of five were predicted to poten-
tially alter natural splice site or activate exonic cryptic splice-sites. When compared with ExAC reference indi-
viduals (DCM: 3.6% vs. ExAC: 2.9%; P = 0.4624) and gnomAD reference individuals (DCM: 3.6% vs. gnomAD: 
3.0%; P = 0.4808), there was no significant enrichment of variants with high potential for defective splicing in 
DCM patients.
Discussion
Recent advancement in high-throughput sequencing technology has unravelled TTN as a major human disease 
gene, mutated in both human skeletal and cardiac muscles disease. Inclusion of the TTN gene in genetic screening 
for DCM has led to an increase in diagnostic rate for adult DCM by at least 18% and 25% respectively in sporadic 
and familial DCM cases8–10,27,28. Much attention has been focused on the assessment and clinical interpretation of 
frameshift, nonsense and splice-site variants, leading to a truncation of TTN, leaving missense and NFS-INDELs 
variants in this major human disease gene unassessed and unexplored. Consequently, these variants are difficult 
to assess and interpret in the clinical diagnostic workflow.
DCM is a genetically heterogeneous disorder and multiple genes have been implicated in the pathogenesis of 
DCM. Truncations of the giant sarcomeric protein, TTN, are to date, the most common genetic cause of DCM, 
accounting for about 20% of cases, and are overrepresented in the A-band region of the protein. Such A-band and/
or distal I-band TTNtv have been estimated to have nearly 98% chance of being disease causing when identified in 
unselected DCM patients7. Interestingly, a recent study showed a significant association of TTNtv in constitutive 
exons throughout TTN protein with DCM29. Furthermore, it has been shown that TTNtv rarely cause pediatric 
DCM but the gene typically expresses the disease at middle-age30. In addition, we and others have addressed 
several issues and challenges associated with the clinical assessment and interpretation of TTNtv in both research 
and clinical diagnostic setting7,9,12–14. In contrast, the role and contribution of missense and NFS-INDELs variants 
in this gene has been poorly addressed so far.
In this European multi-centre DCM study, we assessed the possible role of TTN missense and NFS-INDELs 
variants in DCM. By analyzing TTN variants in: 1) a large primary DCM cohort (n = 530), 2) the widely used 
ExAC reference individuals, and 3) the largest available gnomAD database reference individuals, we showed that 
there is a statistically insignificant enrichment of rare TTN missense and NFS-INDEL variants in DCM patients 
compared with reference individuals. This observation holds even when considering different TTN regions, sug-
gesting that TTN missense and NFS-INDEL variants do not cause DCM and should therefore be classified as 
“likely benign” in clinical diagnostic settings. Using stringent bioinformatic filtering criteria, we identified rare 
TTN missense variants predicted deleterious in 7.0% of primary DCM cases as against 5.7% in gnomAD refer-
ence individuals (OR = 1.2; P = 0.22). When considering different TTN domains (Z-disk, I-band, A-band and 
M-band), we identified no enrichment of these variants in DCM patients compared to reference individuals.
A recent study assessing the role of TTN missense variants identified “severe” missense variants in 25.2% 
(37/147) of DCM probands15. We randomly selected five “severe” missense variants as published by the authors 
and applied our bioinformatic filtering strategy. Of note, 40% (2/5) of these “severe” variants were found in at 
least seven gnomAD database reference individuals, and as such would not be considered “deleterious” using our 
approach. Interestingly, five probands in the study were double heterozygous for a “severe” TTN missense variant 
and a pathogenic (P)/likely pathogenic (LP) variant in LMNA, MYH7 and SCN5A. Three (3/5) of these patients 
harboured a P/LP LMNA variant in addition to “severe” TTN variant. Two of the “severe” TTN missense variants 
were later reclassified by the authors as “unlikely” disease associated, possibly due to lack of segregation, and third 
patient harbouring a P/LP LMNA variant co-occurring with a “severe” TTN missense variant had undergone 
heart transplantation15. In another study of an extended DCM family with 14 affected subjects, four had severe 
DCM requiring heart transplantation in early adulthood31. In all affected patients, the P/LP LMNA p.(Lys219Thr) 
variant was identified. In addition to this variant, a TTN missense variant, p.(Leu4855Phe), was identified in all 
Figure 3. Spatial distribution of rare TTN missense variants in DCM cohort and reference population. Titin 
is linearly depicted with its 152 Ig-like domains in purple and 132 fibronectin type III domains in green. TTN 
missense variants identified in patients as well as ExAC and gnomAD reference individuals are shown as 
coloured bars. Bisque bar represents the number of transcripts (TCI). Variants are shown relative to the Meta 
transcript position. The dark grey bars indicate exons unique to the Meta transcript. The dashed lines below the 
number of transcripts schematic indicate the location of variants within the sarcomere.
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four patients with severe phenotypes, all of whom had transplantation at a younger age compared to those with 
only LMNA p.(Lys219Thr) variant. Although this may suggest that TTN missense variants can modify disease 
severity, the TTN p.(Leu4855Phe) is found heterozygous in 15 individuals in gnomAD reference population and 
the position is multi-allelic, thus stronger evidence is needed before scientific interpretation of potential modifier 
role can be inferred.
Disruption of natural splice sites by point mutations can result in exon skipping, activation of cryptic 
splice-site, and rarely intron retention32, with activation of cryptic splice-site being the second most frequent 
consequence of such mutations. Such point mutations, put together, account for 10–15% of all mutations causing 
human inherited disease33,34. By analyzing missense variants located near exon-intron boundaries (splice-region) 
of TTN, we identified five rare splice-region missense variants in DCM patients. Two (40%) of these five 
splice-region missense variants were predicted to disrupt natural splice-site. To test for possible enrichment of 
this event in DCM patients, we randomly and iteratively selected five rare splice-regions variants from gnomAD 
and tested their potential to alter splicing. Surprisingly, two (40%) of the five randomly chosen splice-region 
missense variants were predicted to alter splicing, suggesting that splice-region missense variants identified in 
our DCM cohort do not carry higher risk of splicing defect than any other splice-region missense variants in the 
population.
DCM cohorts in this study were sequenced using high coverage sequencing assays yielding more uniform 
coverage even across difficult-to-sequence regions that may alone increase likelihood of finding slightly higher 
variant counts from DCM cohorts compared to the population databases. If we overestimate that DCM has 
a prevalence of 1 per 500 and further speculate that TTN missense variants would account 10% of all DCM cases 
leading to a frequency of 1 per 5000 (0.02%) in TTN missense positive DCM. However, 5.7% of gnomAD refer-
ence population have rare missense variant predicted deleterious by in-silico tools, thus 99.7% of these missense 
variants are not expected to cause DCM in monogenic manner. Thus, these variants should be classified as likely 
benign in clinical and diagnostic workflow as far as more understanding have been gathered of them individually 
and as a group.
Rare NFS-INDELs affecting at least five transcripts of TTN (TCI ≥ 5) were identified in 0.37% (2/530) of 
DCM patients as against 0.21% (255/123136) in gnomAD reference individuals (OR = 1.8; P = 0.3). Failure to 
show significant enrichment of NFS-INDELs in our DCM cohort suggests that the vast majority of these variants 
are non-contributory to the monogenic etiology of DCM.
Limitations. We acknowledge the following limitations: The health status of reference individuals used is 
not known even though curators of reference population databases have made every effort to exclude individuals 
with severe pediatric diseases from these cohorts. Moreover, we had limited evidence of the effect of predicted 
deleterious TTN missense variants in patients with other P/LP variants including TTNtv. Functional analysis of 
predicted deleterious TTN missense and NFS-INDELs was beyond the scope of this study; and we recommend 
that such should be combined with segregation information and de novo status to reclassify the variants.
Conclusion
The current data revealed that predicted deleterious TTN missense and NFS-INDEL variants are not significantly 
enriched in a large group of DCM patients compared to control populations, and should therefore be classified 
as likely benign in a clinical diagnostic setting. Nevertheless, it cannot be excluded that some rare TTN missense 
variants might have modifier effect for the phenotype.
Methods
Patient Cohorts and Clinical Evaluation. This European multi-centre study was approved by institu-
tional ethical committees of the University of Helsinki, Academic Medical Centre (Amsterdam, the Netherlands), 
and University Medical Centre (Groningen, the Netherlands) and informed consent was obtained from all sub-
jects. The DCM cohort in this study comprised of 530 unrelated primary DCM patients of European origin. The 
patients were recruited at three major cardiogenetic centres in Finland (Helsinki; n = 145) and the Netherlands 
(Amsterdam; n = 216, and Groningen; n = 169). All patients fulfilled the diagnostic criteria for DCM (LV size/
volume >117% or >2 SD of the reference value and LV-EF <45%)35.
Genetic Studies of DCM. Genomic DNA was extracted from patients’ blood samples by standard pro-
cedures and guidelines. TTN was sequenced in a total of 530 primary DCM patients using targeted panels of 
increasing sizes as previously described8,27. Irrespective of the sequencing panel used, sequence data from each 
patient was processed uniformly following GATK best practices recommendation to identify genetic vari-
ants36. Identified variants were annotated using Ensembl’s Variant Effect Predictor (VEP v87) tool37, and SIFT38, 
PolyPhen39, and MutationTaster40 pathogenicity scores and predictions were obtained for each missense variant 
via the database of nonsynonymous SNP functional prediction (dbNSFPv2.9.2)41. Rare TTN missense variants 
predicted deleterious by the three prediction tools were considered candidate risk variants. NFS-INDELs were 
assessed using the Transcript Count Index (TCI) as previously published7.
Analysis of TTN Missense and NFS-INDELs Variants in the Population. Exonic boundaries of TTN 
in build 37 of the human genome (hg19) were downloaded from the Ensembl Genome Browser (www.ensembl.
org), and were used to query ExAC and gnomAD databases (accessed 23 July 2017) for TTN exonic variants. 
Extracted variants were filtered for quality (Phred Quality Score 29) and coverage (15.0X), and calls that passed 
all quality filters were used for downstream analysis. The two datasets were re-annotated using VEP v87, pro-
cessed uniformly to identify spectrum and distribution of missense and NFS-INDELS mutations in the reference 
population.
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Variant Mapping to Uniprot Protein Domain. To allow inclusion of variants located in exons not pres-
ent in the principal cardiac long isoform (N2BA), otherwise known as the canonical transcript with the Uniprot 
ID Q8WZ42-1, the location of variants identified in DCM patients as well as in the reference population was 
reported with respect to the Meta transcript annotation - (ENST00000589042/NM_001267550). Protein domain 
annotation for the Uniprot consensus sequence Q8WZ42-1 was transferred to the inferred Meta transcript as 
described earlier7,12.
In-silico Splicing Defect Prediction. The effect of splice-region missense variants on splicing effi-
ciency were predicted with five different tools – Human Splicing Finder42,43, Splice Site Prediction by Neural 
Network (NNSPLICE)44, MaxEntScan45, GeneSplicer46, and Splice Site Finder, via Alamut splicing software v2.0 
(Interactive Biosoftware, France) using default settings in all predictions. Controls for each rare splice-region 
missense variant were selected from gnomAD from near-by genomic location and with similar allele frequency.
Statistical Analysis. Between groups comparisons for categorical variables were performed using χ2 test if 
appropriate, otherwise, Fisher’s exact test. For non-parametric and continuous variables, between groups com-
parisons were done using Mann–Whitney U tests and independent samples t-tests combined with Levene’s tests 
respectively. Bonferroni correction was performed on all analyses to adjust for multiple testing. All statistical 
analyses were done using R statistical software (version 3.3.3).
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